

intereststâ€"Â â€"Â â€"Â (10)(10)Balance at November 3, 202352Â \$395Â \$1,413Â \$20Â \$â€"Â \$1,828Â (1)Â Â Â During the three months ended NovemberÂ 1, 2024 and NovemberÂ 3, 2023, shares withheld for taxes related to stock-based compensation arrangements amounted to \$2Â million and \$1Â million, respectively. During the nine months ended NovemberÂ 1, 2024 and NovemberÂ 3, 2023, shares withheld for taxes related to stock-based compensation arrangements amounted to \$25Â million and \$21Â million, respectively. See accompanying notes to condensed consolidated financial statements.-4-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)Â Nine Months EndedÂ November 1, 2024November 3, 2023Â (in millions)Cash flows from operating activities:Â Net income\$264Â \$438Â Adjustments to reconcile net income to net cash provided by operating activities:Â Depreciation and amortization104Â 106Â Deferred income taxes(15)(33)Stock-based compensation expense38Â 42Â Gain on sale of equity method investments and long-lived assets(5)(3)Gain on divestituresâ€"Â (247)Other(4)(1)Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of divestitures:Â Â Receivables(108)(142)Prepaid expenses and other current assets31Â 13Â Other assets10Â 5Â Accounts payable and accrued liabilities121Â 120Â Accrued payroll and employee benefits(59)(4)Income taxes payable(2)21Â Operating lease assets and liabilities, net(7)(3)Other long-term liabilities11Â 21Â Net cash provided by operating activities379Â 333Â Cash flows from investing activities:Â Â Expenditures for property, plant, and equipment(21)(16)Purchases of marketable securities(11)(6)Sales of marketable securities10Â 5Â Proceeds from sale of long-lived assetsâ€"Â 3Â Proceeds from sale of equity method investments10Â â€"Â Proceeds from divestituresâ€"Â 356Â Cash divested upon deconsolidation of joint ventureâ€"Â (8)Other(3)(10)Net cash (used in) provided by investing activities(15)324Â Cash flows from financing activities:Â Â Dividend payments to stockholders(57)(60)Principal payments on borrowings(1,056)(275)Issuances of stock14Â 13Â Stock repurchased and retired or withheld for taxes on equity awards(425)(293)Excise tax payments on stock repurchases(3)â€"Â Proceeds from borrowings1,114Â 160Â Net cash used in financing activities(413)(455)Net (decrease) increase in cash, cash equivalents and restricted cash(49)202Â Cash, cash equivalents and restricted cash at beginning of period103Â 118Â Cash, cash equivalents and restricted cash at end of period\$54Â \$320Â See accompanying notes to condensed consolidated financial statements.-5-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)Note 1â€"Business Overview and Summary of Significant Accounting Policies:OverviewScience Applications International Corporation (collectively, with its consolidated subsidiaries, the "Company") is a leading provider of technical, engineering and enterprise information technology ("IT") services primarily to the U.S.Â government. The Company integrates emerging technology securely and in real-time into mission critical operations that modernize and enable national imperatives. The Company provides these services for large, complex projects with a targeted emphasis on higher-end, differentiated technology services and solutions that accelerate and transform secure and resilient digital environments through system development, modernization, integration, and sustainment to drive enterprise and mission outcomes. Effective February 3, 2024, the first day of fiscal 2025, the Company completed a business reorganization which replaced its previous two customer facing operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The Company's five business groups, which are also its operating segments, are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Companyâ€"Â s two reportable segments are the Defense and Intelligence segment and the Civilian segment. The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy. The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customersâ€"Â entire IT infrastructure. The Company's Innovation Factory supports the operating segments by developing enterprise-class solutions which are delivered to the Company's customers as stand-alone solutions or integrated with and aligned to product offerings through the operations of the business to meet complex customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, and cybersecurity. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions and works with customers to enhance solutions going forward. Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate activities. See Note 11â€"Business Segments Information for additional information. Within this report, the Company has recast historical financial information to reflect the new reportable segments. The recast historical information has no impact on the Company's previously reported condensed consolidated financial statements.Principles of Consolidation and Basis of PresentationReferences to "financial statements" refer to the condensed consolidated financial statements of the Company, which include the statements of income and comprehensive income, balance sheets, statements of equity and statements of cash flows. These financial statements were prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). All intercompany transactions and account balances within the Company have been eliminated. -6-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. Interest income was reclassified from "Other (income) expense, net" to "Interest expense, net" on the condensed consolidated statements of income, gains on divestitures, net of transaction costs were reclassified from "Other operating (income) expense" to "(Gain) loss on divestitures, net of transaction costs" on the condensed consolidated statements of income, and "Accounts Payable" is now presented separately from "Other accrued liabilities" on the condensed consolidated balance sheets. The results reported in these financial statements are not necessarily indicative of results that may be expected for the entire year and should be read in conjunction with the information contained in the Companyâ€"Â s Annual Report on Form 10-K for the year ended FebruaryÂ 2, 2024. Use of EstimatesThe preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Significant estimates inherent in the preparation of the financial statements may include, but are not limited to, estimated profitability of long-term contracts, income taxes, fair value measurements, fair value of goodwill and other intangible assets, pension and defined benefit plan obligations, and contingencies. Estimates have been prepared by management on the basis of the most current and best available information at the time of estimation and actual results could differ from those estimates.Reporting PeriodsThe Company utilizes a 52/53 week fiscal year ending on the Friday closest to JanuaryÂ 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2025 began on February 3, 2024 and ends on JanuaryÂ 31, 2025, while fiscal 2024 began on February 4, 2023 and ended on FebruaryÂ 2, 2024.Operating CycleThe Companyâ€"Â s operating cycle may be greater than one year and is measured by the average time intervening between the inception and the completion of contracts.Derivative Instruments Designated as Cash Flow HedgesDerivative instruments are recorded on the condensed consolidated balance sheets at fair value. Unrealized gains and losses on derivatives designated as cash flow hedges are reported in other comprehensive income (loss) and reclassified to earnings in a manner that matches the timing of the earnings impact of the hedged transactions. Settlement amounts related to derivatives designated as cash flow hedges are presented within operating activities on the condensed consolidated statement of cash flows.The Companyâ€"Â s fixed interest rate swaps are considered over-the-counter derivatives, and their fair value is calculated using a standard pricing model for interest rate swaps with contractual terms for maturities, amortization and interest rates. Level 2, or market observable inputs (such as yield and credit curves), are used within the standard pricing models in order to determine fair value. The fair value is an estimate of the amount that the Company would pay or receive as of a measurement date if the agreements were transferred to a third party. See Note 8â€"Derivative Instruments Designated as Cash Flow Hedges for further discussion on the Companyâ€"Â s derivative instruments designated as cash flow hedges.Marketable SecuritiesInvestments in marketable securities consist of equity securities, which are recorded at fair value using observable inputs such as quoted prices in active markets (Level 1). As of NovemberÂ 1, 2024 and FebruaryÂ 2, 2024, the fair value of the Company's investments totaled \$36 million and \$32Â million, respectively, and are included in "Other assets" on the condensed consolidated balance sheets. The Company's investments are primarily held in a custodial account, which includes investments to fund its deferred compensation plan liabilities.-7-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)Sale of Equity Method InvestmentOn August 30, 2024, Morpheus Data, one of the Companyâ€"Â s unconsolidated venture investments, completed a transaction to sell all its outstanding equity, including the Company's equity investment, to Hewlett Packard Enterprise (NYSE: HPE). The transaction resulted in a pre-tax gain of \$5Â million which is included within "Other operating (income) expense" on the condensed consolidated statements of income.Cash, Cash Equivalents and Restricted CashThe following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported on the condensed consolidated balance sheets for the periods presented:Â November 1, 2024February 2, 2024Â (in millions)Cash and cash equivalents\$46Â \$94Â Restricted cash included in prepaid expenses and other current assets4Â 4Â Restricted cash included in other assets4Â 5Â Cash, cash equivalents and restricted cash\$54Â \$103Â Restructuring CostsThe Company periodically initiates restructuring activities to support business strategies, realign resources, and enhance its operational efficiency. Restructuring costs may include severance and other employee related termination costs, costs associated with consolidating or closing facilities and consulting costs. Restructuring costs for the nine months ended NovemberÂ 1, 2024 were \$4Â million

and were primarily related to activities associated with the reorganization of its business sectors into business groups and the optimization and consolidation of certain facilities. Restructuring costs for the three and nine months ended November 3, 2023 were \$2.4 million and \$8.4 million, respectively, and were primarily associated with the optimization and consolidation of certain facilities. Restructuring costs are presented within "Selling, general and administrative expenses" on the condensed consolidated statements of income. Accounting Standards Update In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" (Subtopic 220-40): Disaggregation of Income Statement Expenses. The standard includes new disclosure requirements relating to specified categories of expenses (purchases of inventory, employee compensation, depreciation, and amortization) that are included in certain expense captions presented on the face of the income statement. The standard is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments can be applied on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption of this standard on its financial statement disclosures. In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The standard includes amendments that enhance annual income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The standard is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments can be applied on a prospective or retrospective basis. The Company plans to adopt this standard in fiscal 2026 and is currently evaluating the impact of adoption of this standard on its financial statement disclosures. -8- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures", to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Amongst other amendments, the standard requires annual and interim disclosures of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"), and interim disclosures about a reportable segment's profit or loss and assets that are currently required annually. This standard does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the annual disclosure in fiscal 2025 and the interim disclosure in fiscal 2026 and is currently evaluating the impact of adoption of this standard on its financial statement disclosures. Note 2 - Earnings Per Share, Share Repurchases and Dividends: Earnings Per Share ("EPS") Basic EPS is computed by dividing net income by the basic weighted-average number of shares outstanding. Diluted EPS is computed similarly to basic EPS, except the weighted-average number of shares outstanding is increased to include the dilutive effect of outstanding stock-based awards. The dilutive effect of outstanding stock-based awards is computed using the treasury stock method. The following table provides a reconciliation of the weighted-average number of shares outstanding used to compute basic and diluted EPS for the periods presented:

Three Months Ended November 1, 2024	November 3, 2023	November 1, 2024	November 3, 2023
(in millions)		(in millions)	
Basic weighted-average number of shares outstanding	49.4	52.8	50.6
Dilutive common share equivalents - stock options and other stock-based awards	0.4	0.5	0.5
Diluted weighted-average number of shares outstanding	49.8	53.3	51.1

 Antidilutive stock awards excluded from the weighted-average number of shares outstanding used to compute diluted EPS for the three and nine months ended November 1, 2024 and November 3, 2023 were immaterial. Share Repurchases The Company may repurchase shares in accordance with established repurchase plans. The Company retires its common stock upon repurchase with the excess over par value allocated to additional paid-in capital. When repurchases for the period exceed total additional paid-in capital, the excess repurchases are recorded as a reduction to retained earnings. The Company has not made any material purchases of common stock other than in connection with established share repurchase plans. In June 2022, the number of shares of the Company's common stock that may be repurchased under the Company's existing repurchase plan was increased by 8.0 million shares, bringing the total authorized shares to be repurchased under the plan to approximately 24.4 million shares. As of November 1, 2024, the Company has repurchased approximately 23.4 million shares of its common stock under the plan. Dividends The Company declared and paid a quarterly dividend of \$0.37 per share of its common stock during the three months ended November 1, 2024. -9- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 3 - Revenues: Changes in Estimates on Contracts Changes in estimates of revenues, cost of revenues or profits related to performance obligations satisfied over time are recognized in operating income in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can occur routinely over the performance period for a variety of reasons, which include: changes in scope; changes in cost estimates due to unanticipated cost growth or reassessments of risks impacting costs; changes in the estimated transaction price, such as variable amounts for incentive or award fees; and performance being better or worse than previously estimated. A significant portion of the Company's contracts recognize revenue on performance obligations using a cost input measure (cost-to-cost), which requires estimates of total costs at completion. In cases when total expected costs exceed total estimated revenues for a performance obligation, the Company recognizes the total estimated loss in the quarter identified. Total estimated losses are inclusive of any unexercised options that are probable of award, only if they increase the amount of the loss. Aggregate net changes in estimates on contracts accounted for using the cost-to-cost method of accounting were recognized in operating income as follows:

Three Months Ended November 1, 2024	November 3, 2023	November 1, 2024	November 3, 2023
(in millions, except per share amounts)		(in millions, except per share amounts)	
Net favorable (unfavorable) adjustments	\$15.4	\$2.4	\$15.4
Diluted EPS impact	\$0.26	\$0.04	\$0.23
\$0.09	\$0.09	\$0.09	\$0.09
Revenues were \$13.4 million and \$14.4 million higher for the three and nine months ended November 1, 2024 and \$4.4 million and \$8.4 million higher for the three and nine months ended November 1, 2023, respectively, due to net revenue recognized from performance obligations satisfied in prior periods.			

 Disaggregation of Revenues The Company's revenues are generated primarily from long-term contracts with the U.S. government including subcontracts with other contractors engaged in work for the U.S. government. The Company disaggregates revenues by customer, contract type and prime versus subcontractor to the federal government for each of its reportable segments. Disaggregated revenues by customer were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total	
(in millions)		(in millions)			(in millions)			
Department of Defense	\$99.2	\$13.4	\$1,005.4	\$97.5	\$17.4	\$99.2	\$13.4	\$1,005.4
Intelligence and other federal government agencies	51.7	41.3	93.0	49.9	36.4	86.3	41.3	93.0
Commercial, state and local governments and international	6.4	3.5	4.1	5.4	3.5	4.0	4.1	5.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4	\$461.4

 -10- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Nine Months Ended November 1, 2024 November 3, 2023 Defense and Intelligence Civilian Total Defense and Intelligence Civilian Total (in millions) Department of Defense \$2,916.4 \$15.4 \$2,931.4 \$2,961.4 \$21.4 \$2,982.4 Intelligence and other federal government agencies 1,430.4 1,158.4 2,588.4 1,492.4 1,119.4 2,611.4 Commercial, state and local governments and international 20.4 102.4 122.4 12.4 102.4 114.4 Total \$4,366.4 \$1,275.4 \$5,641.4 \$4,465.4 \$1,242.4 \$5,707.4 Disaggregated revenues by contract type were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Cost reimbursement	\$1,245.4	\$28.4	\$1,273.4	\$1,188.4	\$19.4	\$1,207.4	\$1,188.4
Time and materials ("T&M")	119.4	287.4	406.4	134.4	248.4	382.4	Firm-fixed price ("FFP")
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4
Other	6.4	3.5	4.4	3.5	4.4	4.4	4.4
Total	\$1,515.4	\$461.4	\$1,976.4	\$1,479.4	\$416.4	\$1,895.4	\$1,515.4

 Disaggregated revenues by prime versus subcontractor were as follows:

Three Months Ended November 1, 2024	November 3, 2023	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)		(in millions)			(in millions)		
Prime contractor to federal government	1,384.4	\$385.4	\$1,769.4	\$1,363.4	\$347.4	\$1,710.4	\$1,363.4
Subcontractor to federal government	125.4	41.4	166.4	111.4	34.4	145.4	106.4

inception to date revenue recognized. RPO does not include unexercised option periods and future task orders expected to be awarded under IDIQ contracts. As of November 1, 2024, the Company had approximately \$5.7 billion of RPO. The Company expects to recognize revenue on approximately 81% of the RPO over the next 12 months and approximately 91% over the next 24 months, with the remaining recognized thereafter. Note 4—Divestitures: FSA Amendment On February 4, 2023, the Company sold 0.1% of its 50.1% majority ownership interest in Forfeiture Support Associates J.V. ("FSA") to its sole joint venture partner for a nominal amount. In conjunction with the sale, the Company remeasured its retained investment in FSA to a fair value of \$14 million. As a result of the sale and amendment to the joint venture operating agreement of FSA, the Company no longer controls the joint venture and will account for its retained interest as an equity method investment as of the date of the transaction. The equity method investment is included within "Other assets" on the condensed consolidated balance sheets. The remeasurement resulted in a gain of \$7 million which is included within "(Gain) loss on divestitures, net of transaction costs" on the condensed consolidated statements of income and is reflected within "Gain on divestitures" on the condensed consolidated statements of cash flows for the nine months ended November 3, 2023. The Company estimated the fair value of its retained investment in FSA based on Level 3 inputs of the fair value hierarchy. The Company used the income approach which involves the use of estimates and assumptions, including revenue growth rates, projected operating margins, discount rates and terminal growth rates.

12-Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Sale of Logistics and Supply Chain Management Business On May 6, 2023, the Company closed the sale of its logistics and supply chain management business ("Supply Chain Business") to ASRC Federal Holding Company, LLC ("ASRC Federal") for \$356 million in cash, including \$355 million received at closing and a preliminary post-closing adjustment for working capital. The Company recognized the cash as "Proceeds from divestitures" on the condensed consolidated statements of cash flows. The sale enables the Company to focus its resources on long-term strategic growth areas. During the second quarter of fiscal 2024, the Company recorded a preliminary pre-tax gain of \$233 million, net of \$7 million of transaction costs, which is included within "(Gain) loss on divestitures, net of transaction costs" on the condensed consolidated statements of income. The disposition did not represent a strategic shift in operations that would have a material effect on the Company's operations and financial results, and accordingly has not been presented as discontinued operations. The major classes of assets and liabilities divested were as follows: (in millions)

Assets:	Receivables, net	\$46
Inventorys, net	72	
Prepaid expenses	181	
Goodwill	60	
Operating lease right of use assets	2	
Total assets	181	
Liabilities:		
Accounts payable	62	
Accrued payroll and employee benefits	1	
Other accrued liabilities	1	
Operating lease liabilities	1	
Total liabilities	65	
Divested	65	

In connection with the sale, the Company and ASRC Federal entered into certain transition services agreements pursuant to which the Company provided certain services to ASRC Federal through the first quarter of fiscal 2025 on a cost reimbursable basis. The transition services included certain IT, finance and other services necessary to support the transition of the sale.

Note 5—Goodwill and Intangible Assets: Goodwill The following table presents the carrying value of goodwill by reportable segment: November 1, 2024/February 2, 2024 (in millions)

Segment	Carrying Value
Defense and Intelligence	\$2,001
Civilian	850
Total	\$2,851

Goodwill is not amortized, but rather tested for potential impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The goodwill impairment test is performed at

13-Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

the reporting unit level. As a result of the internal reorganization on February 3, 2024, the Company reallocated its goodwill to its five new goodwill reporting units. The Company performed a goodwill impairment test immediately before and after the reorganization, both of which resulted in no impairment. For the goodwill impairment test immediately after the reorganization, the Company performed a quantitative assessment of its goodwill as of February 3, 2024 for its five new goodwill reporting units. The Company estimated the fair value of each reporting unit using a 50:50 weighting of fair values derived from an income approach and market approach. Under the income approach, the Company estimated the fair value of its reporting units using a multi-year discounted cash flow model involving assumptions about projected future revenue growth, operating margins, income tax rates, capital expenditures, discount rate, and terminal value. Under the market approach, the Company estimated the fair value of its reporting units based on multiples of earnings derived from observable market data of comparable public companies.

Intangible Assets: Intangible assets, all of which were finite-lived, consisted of the following: November 1, 2024/February 2, 2024

Category	Carrying Value
Customer relationships	\$1,462
Technology	10
Trade name	10
Trade name	1
Intangible assets	1
Total intangible assets	1,473

\$ (666)

\$ 807

\$ 1,473

\$ (579)

\$ 894

Amortization expense related to intangible assets was \$29 million and \$87 million for the three and nine months ended November 1, 2024, respectively, and \$28 million and \$86 million for the three and nine months ended November 3, 2023, respectively. There were no intangible asset impairment losses during the periods presented. As of November 1, 2024, the estimated future annual amortization expense related to intangible assets is as follows:

Period	Remaining Amortization (in millions)
2025	\$28
2026	\$115
2027	\$115
2028	\$115
2029	\$115
2030	\$115
2031	\$115
2032	\$115
2033	\$115
2034	\$115
2035	\$115
2036	\$115
2037	\$115
2038	\$115
2039	\$115
2040	\$115
2041	\$115
2042	\$115
2043	\$115
2044	\$115
2045	\$115
2046	\$115
2047	\$115
2048	\$115
2049	\$115
2050	\$115
2051	\$115
2052	\$115
2053	\$115
2054	\$115
2055	\$115
2056	\$115
2057	\$115
2058	\$115
2059	\$115
2060	\$115
2061	\$115
2062	\$115
2063	\$115
2064	\$115
2065	\$115
2066	\$115
2067	\$115
2068	\$115
2069	\$115
2070	\$115
2071	\$115
2072	\$115
2073	\$115
2074	\$115
2075	\$115
2076	\$115
2077	\$115
2078	\$115
2079	\$115
2080	\$115
2081	\$115
2082	\$115
2083	\$115
2084	\$115
2085	\$115
2086	\$115
2087	\$115
2088	\$115
2089	\$115
2090	\$115
2091	\$115
2092	\$115
2093	\$115
2094	\$115
2095	\$115
2096	\$115
2097	\$115
2098	\$115
2099	\$115
2100	\$115
2101	\$115
2102	\$115
2103	\$115
2104	\$115
2105	\$115
2106	\$115
2107	\$115
2108	\$115
2109	\$115
2110	\$115
2111	\$115
2112	\$115
2113	\$115
2114	\$115
2115	\$115
2116	\$115
2117	\$115
2118	\$115
2119	\$115
2120	\$115
2121	\$115
2122	\$115
2123	\$115
2124	\$115
2125	\$115
2126	\$115
2127	\$115
2128	\$115
2129	\$115
2130	\$115
2131	\$115
2132	\$115
2133	\$115
2134	\$115
2135	\$115
2136	\$115
2137	\$115
2138	\$115
2139	\$115
2140	\$115
2141	\$115
2142	\$115
2143	\$115
2144	\$115
2145	\$115
2146	\$115
2147	\$115
2148	\$115
2149	\$115
2150	\$115
2151	\$115
2152	\$115
2153	\$115
2154	\$115
2155	\$115
2156	\$115
2157	\$115
2158	\$115
2159	\$115
2160	\$115
2161	\$115
2162	\$115
2163	\$115
2164	\$115
2165	\$115
2166	\$115
2167	\$115
2168	\$115
2169	\$115
2170	\$115
2171	\$115
2172	\$115
2173	\$115
2174	\$115
2175	\$115
2176	\$115
2177	\$115
2178	\$115
2179	\$115
2180	\$115
2181	\$115
2182	\$115
2183	\$115
2184	\$115
2185	\$115
2186	\$115
2187	\$115
2188	\$115
2189	\$115
2190	\$115
2191	\$115
2192	\$115
2193	\$115
2194	\$115
2195	\$115
2196	\$115
2197	\$115
2198	\$115
2199	\$115
2200	\$115
2201	\$115
2202	\$115
2203	\$115
2204	\$115
2205	\$115
2206	\$115
2207	\$115
2208	\$115
2209	\$115
2210	\$115
2211	\$115
2212	\$115
2213	\$115
2214	\$115
2215	\$115
2216	\$115
2217	\$115
2218	\$115
2219	\$115
2220	\$115
2221	\$115
2222	\$115
2223	\$115
2224	\$115
2225	\$115
2226	\$115
2227	\$115
2228	\$115
2229	\$115
2230	\$115
2231	\$115
2232	\$115
2233	\$115
2234	\$115
2235	\$115
2236	\$115
2237	\$115
2238	\$115
2239	\$115
2240	\$115
2241	\$115
2242	\$115
2243	\$115
2244	\$115
2245	\$115
2246	\$115
2247	\$115
2248	\$115
2249	\$115
2250	\$115
2251	\$115
2252	\$115
2253	\$115
2254	\$115
2255	\$115
2256	\$115
2257	\$115
2258	\$115
2259	\$115
2260	\$115
2261	\$115
2262	\$115
2263	\$115
2264	\$115
2265	\$115
2266	\$115
2267	\$115
2268	\$115
2269	\$115
2270	\$115
2271	\$115
2272	\$115
2273	\$115
2274	\$115
2275	\$115
2276	\$115
2277	\$115
2278	\$115
2279	\$115
2280	\$115
2281	\$115
2282	\$115
2283	\$115
2284	\$115
2285	\$115
2286	\$115
2287	\$115
2288	\$115
2289	\$115
2290	\$115
2291	\$115
2292	\$115
2293	\$115
2294	\$115
2295	\$115
2296	\$115
2297	\$115
2298	\$115
2299	\$115
2300	\$115
2301	\$115
2302	\$115
2303	\$115
2304	\$115
2305	\$115
2306	\$115
2307	\$115
2308	\$115
2309	\$115
2310	\$115
2311	\$115
2312	\$115
2313	\$115
2314	\$115
2315	\$115
2316	\$115
2317	\$115
2318	\$115
2319	\$115
2320	\$115
2321	\$115
2322	\$115
2323	\$115
2324	\$115
2325	\$115
2326	\$115
2327	\$115
2328	\$115
2329	\$115
2330	\$115
2331	\$115
2332	\$115
2333	\$115
2334	\$115
2335	\$115
2336	\$115
2337	\$115
2338	\$115
2339	\$115
2340	\$115
2341	\$115
2342	\$115
2343	\$115
2344	\$115
2345	\$115
2346	\$115
2347	\$115
2348	\$115
2349	\$115
2350	\$115
2351	\$115
2352	\$115
2353	\$115
2354	\$115
2355	\$115
2356	\$115
2357	\$115
2358	\$115
2359	\$115
2360	\$115
2361	\$115
2362	\$115
2363	\$115
2364	\$115
2365	\$115
2366	\$115
2367	\$115
2368	\$115
2369	\$115
2370	\$115
2371	\$115
2372	\$115
2373	\$115
2374	\$115
2375	\$115
2376	\$115
2377	\$115
2378	\$115
2379	\$115
2380	\$115
2381	\$115
2382	\$115
2383	\$115
2384	\$115
2385	\$115
2386	\$115
2387	\$115
2388	\$115
2389	\$115
2390	\$115
2391	\$115
2392	\$115
2393	\$115
2394	\$115
2395	\$115
2396	\$115
2397	\$115
2398	\$115
2399	\$115
2400	\$115
2401	\$115
2402	\$115
2403	\$115
2404	\$115
2405	\$115
2406	\$115
2407	\$115
2408	\$115
2409	\$115
2410	\$115
2411	\$115
2412	\$115
2413	\$115
2414	\$115
2415	\$115
2416	\$115
2417	\$115
2418	\$115
2419	\$115
2420	\$115
2421	\$115
2422	\$115
2423	\$115
2424	\$115
2425	\$115
2426	\$115
2427	\$115
2428	\$115
2429	\$115
2430	\$115
2431	\$115
2432	\$115
2433	\$115
2434	\$115
2435	\$115
2436	\$115
2437	\$115
2438	\$115
2439	\$115
2440	\$115
2441	\$115
2442	\$115
2443	\$115
2444	\$115
2445	\$115
2446	\$115
2447	\$115
2448	\$115
2449	\$115
2450	\$115
2451	\$115
2452	\$115
2453	\$115
2454	\$115
2455	\$115
2456	\$115
2457	\$115
2458	\$115
2459	\$115
2460	\$115
2461	\$115
2462	\$115
2463	\$115</

amounts under the Revolving Credit Facility range from 0.125% to 0.25% per annum based on the Company's leverage ratio. As of November 1, 2024, the Company was in compliance with the covenants under its Credit Facility. As of November 1, 2024 and February 2, 2024, the carrying value of the Company's outstanding debt obligations approximated its fair value. The fair value of debt is calculated using Level 2 inputs, based on interest rates available for debt with terms and maturities similar to the Company's Term Loan Facilities and Senior Notes. Maturities of debt as of November 1, 2024 are: Fiscal Year Total (in millions) Remainder of 2025 \$139A 2026 \$113A 2027 \$128A 2028 \$89A 2029 \$40A Thereafter 486A Total principal payments \$2,168A Note 8A Derivative Instruments Designated as Cash Flow Hedges: The Company's derivative instruments designated as cash flow hedges consist of: A A A A Fair Value of Asset(1) at Notional Amount at November 1, 2024 Pay Fixed Rate Receive Variable Rate Settlement and Termination November 1, 2024 February 2, 2024A (in millions) A A (in millions) Interest rate swaps \$685A 2.96A % 1-month Term SOFR Monthly through October 31, 2025 \$8A \$15A (1)A A A The fair value of the fixed interest rate swap asset is included in "Other assets" on the condensed consolidated balance sheets. The Company is party to fixed interest rate swap instruments that are designated and accounted for as cash flow hedges to manage risks associated with interest rate fluctuations on a portion of the Company's floating rate debt within the Credit Facility. The counterparties to all swap agreements are financial institutions. -16- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) See Note 9A "Changes in Accumulated Other Comprehensive Income (Loss) by Component" for the unrealized change in fair values on cash flow hedges recognized in other comprehensive income (loss) and the amounts reclassified from accumulated other comprehensive income (loss) into earnings for the current and comparative periods presented. During the three months ended November 3, 2023, Interest Rate Swaps due October 31, 2023 matured, which had a notional value of \$450A million upon maturity. The Company estimates that it will reclassify \$8 million of unrealized gains from accumulated other comprehensive income into earnings in the twelve months following November 1, 2024. -17- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 9A "Changes in Accumulated Other Comprehensive Income (Loss) by Component": The following table presents the changes in accumulated other comprehensive income (loss) attributable to the Company's fixed interest rate swap cash flow hedges that are discussed in Note 8A "Derivative Instruments Designated as Cash Flow Hedges and the Company's defined benefit plans. A Unrealized Gains (Losses) on Fixed Interest Rate Swap Cash Flow Hedges (1) Defined Benefit Obligation Adjustment Total A (in millions) Three months ended November 1, 2024 Balance at August 2, 2024 \$6A \$5A \$11A Other comprehensive income before reclassifications 3A A A 3A Amounts reclassified from accumulated other comprehensive income (4)A A (4) Income tax impact A A A Net other comprehensive loss (1)A A (1) Balance at November 1, 2024 \$5A \$5A \$10A Three months ended November 3, 2023 Balance at August 4, 2023 \$19A \$4A \$23A Other comprehensive income before reclassifications 4A A A 4A Amounts reclassified from accumulated other comprehensive income (8)A A (8) Income tax impact 1A A A 1A Net other comprehensive loss (3)A A (3) Balance at November 3, 2023 \$16A \$4A \$20A Nine months ended November 1, 2024 Balance at February 2, 2024 \$11A \$5A \$16A Other comprehensive income before reclassifications 5A A A 5A Amounts reclassified from accumulated other comprehensive income (12)A A (12) Income tax impact 1A A A 1A Net other comprehensive loss (6)A A (6) Balance at November 1, 2024 \$5A \$5A \$10A Nine months ended November 3, 2023 A Balance at February 3, 2023 \$18A \$4A \$22A Other comprehensive income before reclassifications 17A A A 17A Amounts reclassified from accumulated other comprehensive income (20)A A (20) Income tax impact 1A A A 1A Net other comprehensive loss (2)A A (2) Balance at November 3, 2023 \$16A \$4A \$20A (1) The amount reclassified from accumulated other comprehensive income (loss) is included in "Interest expense, net." -18- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 10A "Sales of Receivables": The Company has a Master Accounts Receivable Purchase Agreement ("MARPA Facility") with MUFG Bank, Ltd. (the "Purchaser") for the sale of up to a maximum amount of \$300 million of certain designated eligible receivables with the U.S. government. During the three and nine months ended November 1, 2024, the Company incurred purchase discount fees of \$4A million and \$11 million, respectively. During the three and nine months ended November 3, 2023, the Company incurred purchase discount fees of \$2A million and \$7A million, respectively. The purchase discount fees are presented in "Other (income) expense, net" on the condensed consolidated statements of income and are reflected as cash flows from operating activities on the condensed consolidated statements of cash flows. MARPA Facility activity consisted of the following: Nine Months Ended November 1, 2024 November 3, 2023 (in millions) Beginning balance \$205A \$250A Sale of receivables 3,216A 1,957A Cash collections (3,121)(1,957) Outstanding balance sold to Purchaser (1) 300A 250A Cash collected, not remitted to Purchaser (2) (67)(33) Remaining sold receivables \$233A \$217A (1) A A A For the nine months ended November 1, 2024, the Company recorded a net increase of \$95A million to cash flows from operating activities from sold receivables. For the nine months ended November 3, 2023, there was no net impact to cash flows from operating activities from sold receivables. (2) A A A Primarily represents the cash collected on behalf of but not yet remitted to the Purchaser as of November 1, 2024 and November 3, 2023. This balance is included in "Accounts payable" on the condensed consolidated balance sheets. Note 11A "Business Segments Information": Effective February 3, 2024, the first day of fiscal 2025, the Company completed a business reorganization which replaced its previous two customer facing operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups represent the Company's operating segments and have been aggregated into two reportable segments (Defense and Intelligence, and Civilian) given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company defines its operating segments based on the way the CODM, currently the Company's CEO, manages the operations for the purpose of allocating resources and assessing performance. The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy. The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, AI, mission systems support, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure. Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate. -19- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The CODM reviews and evaluates segment operating performance using segment "Revenues" and "Adjusted operating income (loss)". Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. The segment information for the periods presented was as follows: Three Months Ended November 1, 2024 November 3, 2023 A Defense and Intelligence Civilian Corporate Total Defense and Intelligence Civilian Corporate Total A (in millions) Revenues \$1,515A \$461A \$461A \$1,976A \$1,479A \$416A \$416A \$1,895A Operating income (loss) 130A 37A (7) 160A 106A 54A (17) 143A Depreciation of property, plant, and equipment 1A A 5A 6A 1A A 5A 6A Amortization of intangible assets 12A 12A A 29A 16A 12A A 28A Restructuring and impairment costs A A A A A A A A A A Recovery of restructuring and impairment costs (1)A A A A A A A A A A (1) Adjusted operating income (loss) \$148A \$49A (\$2) \$195A \$123A \$66A (\$11) \$178A (1) A A A Adjustment reflects the portion of restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards. The table below includes a reconciliation of total "Adjusted operating income" to "Income before income taxes" for the three months ended November 1, 2024. Three Months Ended November 1, 2024 November 3, 2023 A (in millions) Adjusted operating income \$195A \$178A Depreciation of property, plant, and equipment (6) (6) Amortization of intangible assets (29) (28) Restructuring and impairment costs A A Recovery restructuring and impairment costs (1)A A Interest expense, net (32) (27) Other (income) expense, net (2) (2) Income before income taxes \$126A \$114A (1) A A A Adjustment reflects the portion of restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards. -20- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Nine Months Ended November 1, 2024 November 3, 2023 A Defense and Intelligence Civilian Corporate Total Defense and Intelligence Civilian Corporate Total A (dollars in millions) Revenues \$4,366A \$1,275A \$5,641A \$4,465A \$1,242A \$5,707A Operating income (loss) 344A 105A (24) 425A 336A 139A 187A 662A Depreciation of property, plant, and equipment 1A A 16A 17A 1A A 18A 19A Amortization of intangible assets 51A 36A A 87A 50A 36A A 86A Acquisition and integration costs (1)A A A (2) (2) A A A Restructuring and impairment costs A A A A A A A A A Recovery of acquisition and integration costs and restructuring and impairment costs (2)A A A (2) (2) A A A (1) (1) (Gain) loss on divestitures, net of transaction costs A A A A A A A A A (240) (240) Adjusted operating income (loss) \$396A \$141A (\$8) \$529A \$387A \$175A (\$27) \$535A (1) A A A Adjustment consists of a reversal of immaterial costs related to the Koverse acquisition. (2) A A A Adjustment reflects the portion of acquisition and integration costs and restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards. The table below includes a reconciliation of total "Adjusted operating income" to "Income before income taxes" for the nine months ended November 1, 2024. Nine Months Ended November 1, 2024 November 3, 2023 A (in millions) Adjusted operating income \$529A \$535A Depreciation of property, plant, and equipment (17) (19) Amortization of intangible assets (87) (86) Acquisition and integration costs (1) A A Restructuring and impairment costs (4) (8) Recovery of

acquisition and integration costs and restructuring and impairment costs(2)2Â 1Â (Gain) loss on divestitures, net of transaction costsâ€”Â 240Â Interest expense, net(97)(88)Other (income) expense, net(7)(2)Income before income taxes\$321Â \$572Â (1)Â A Â A Â Adjustment consists of a reversal of immaterial costs related to the Koverse acquisition.(2)Â A Â A Â Adjustment reflects the portion of acquisition and integration costs and restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.Asset information by segment is not a key measure of performance used by the CODM.-21-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UANAUDITED)Note 12â€”Legal Proceedings and Other Commitments and Contingencies:Legal ProceedingsThe Company is involved in various claims and lawsuits arising in the normal conduct of its business, none of which the Companyâ€™s management believes, based on current information, is expected to have a material adverse effect on the Companyâ€™s financial position, results of operations or cash flows.In April 2022 and October 2023, the Company received Federal Grand Jury Subpoenas in connection with a criminal investigation being conducted by the U.S. Department of Justice, Antitrust Division ("DOJ"). As required by the subpoenas, the Company has provided the DOJ with a broad range of documents related to the investigation, and the Companyâ€™s collection and production process remains ongoing. The Company is fully cooperating with the investigation. At this time, it is not possible to determine whether the Company will incur, or to reasonably estimate the amount of, any fines, penalties or further liabilities in connection with the investigation pursuant to which the subpoenas were issued.AAV Termination for ConvenienceOn August 27, 2018, the Company received a stop-work order from the United States Marine Corps on the Assault Amphibious Vehicle ("AAV") contract and on October 3, 2018 the program was terminated for convenience by the customer. In the third quarter of fiscal 2025, the Company entered into a \$21.2Â million termination settlement agreement with the customer to recover the contract costs associated with the termination, which resulted in an increase to "Revenues" of \$13Â million on the Company's condensed consolidated statements of income for the three and nine months ended November 1, 2024. The settlement agreement releases the customer from all obligation and claims from the Company. Government Investigations, Audits and ReviewsThe Company is routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect, in particular, to its role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. U.S. government agencies, including the Defense Contract Audit Agency ("DCAA"), the Defense Contract Management Agency and others, routinely audit and review a contractorâ€™s performance on government contracts, indirect rates and pricing practices, and compliance with applicable contracting and procurement laws, regulations and standards. They also review the adequacy of the contractorâ€™s compliance with government standards for its business systems. Adverse findings in these investigations, audits, or reviews can lead to criminal, civil or administrative proceedings, and the Company could face disallowance of previously billed costs, penalties, fines, compensatory damages and suspension or debarment from doing business with governmental agencies. Due to the Companyâ€™s reliance on government contracts, adverse findings could also have a material impact on the Companyâ€™s business, including its financial position, results of operations and cash flows.The indirect cost audits by the DCAA of the Companyâ€™s business remain open for certain prior years and the current year. Although the Company has recorded contract revenues based on an estimate of costs that the Company believes will be approved on final audit, the Company does not know the outcome of any ongoing or future audits. If future completed audit adjustments exceed the Companyâ€™s reserves for potential adjustments, the Companyâ€™s profitability could be materially adversely affected.As of NovemberÂ 1, 2024, the Company believes it has adequately reserved for estimated net amounts to be refunded to customers for potential adjustments for indirect cost audits and compliance with U.S. government Cost Accounting Standards.Letters of Credit and Surety BondsThe Company has outstanding obligations relating to letters of credit of \$11 million as of NovemberÂ 1, 2024, principally related to guarantees on insurance policies. The Company also has outstanding obligations relating to surety bonds of \$19 million, principally related to performance and payment bonds on the Companyâ€™s contracts. -22-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UANAUDITED)Note 13â€”Subsequent EventsQuarterly Dividend DeclaredOn December 4, 2024, the Company's Board of Directors declared a quarterly dividend of \$0.37 per share of the Company's common stock payable on January 24, 2025 to stockholders of record on January 10, 2025.Plan Share Repurchase AuthorizationOn December 4, 2024, the Company's Board of Directors authorized the repurchase of up to \$1.2Â billion of the companyâ€™s outstanding common stock. This authorization is effective as of December 16, 2024 and has no expiration date. The share repurchase program will be used as part of the Companyâ€™s capital allocation strategy, which includes returning capital to its shareholders. This share repurchase authorization replaces the Companyâ€™s existing share repurchase program.-23-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis of our financial condition and results of operations and quantitative and qualitative disclosures about market risk should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes. It contains forward-looking statements (which may be identified by words such as those described in â€œRisk Factorsâ€”Forward-Looking Statement Risksâ€ in Part I of the most recently filed Annual Report on Form 10-K), including statements regarding our intent, belief, or current expectations with respect to, among other things, trends affecting our financial condition or results of operations (including our financial targets discussed below under â€œManagement of Operating Performance and Reportingâ€ and â€œLiquidity and Capital Resourcesâ€); backlog; our industry; government budgets and spending; market opportunities; the impact of competition; and the impact of acquisitions and divestitures. Such statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these differences include those discussed below, in â€œRisk Factorsâ€ in Part II of this report and in Part I of the most recently filed Annual Report on Form 10-K. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any changes to our forward-looking statements due to future results or developments.We use the terms "SAIC," the â€œCompany,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ to refer to Science Applications International Corporation and its consolidated subsidiaries.The Company utilizes a 52/53 week fiscal year, ending on the Friday closest to JanuaryÂ 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2025 began on February 3, 2024 and ends on JanuaryÂ 31, 2025, while fiscal 2024 began on February 4, 2023 and ended on FebruaryÂ 2, 2024.Business OverviewWe are a leading technology integrator providing full life cycle services and solutions in the technical, engineering and enterprise information technology ("IT") markets. We developed our brand by addressing our customersâ€™ mission critical needs and solving their most complex problems for over 50 years. As one of the largest pure-play technology service providers to the U.S. government, we serve markets of significant scale and opportunity. Our primary customers are the departments and agencies of the U.S. government. We serve our customers through approximately 1,800 active contracts and task orders and employ approximately 24,000 individuals who are led by an experienced executive team of proven industry leaders. Our long history of serving the U.S. government has afforded us the ability to develop strong and longstanding relationships with some of the largest customers in the markets we serve. Substantially all of our revenues and tangible long-lived assets are generated and located in the United States.Effective February 3, 2024, the first day of fiscal 2025, we completed a business reorganization which replaced our previous two operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups represent our operating segments and have been aggregated into two reportable segments (Defense and Intelligence, and Civilian) given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy. The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customersâ€™ entire IT infrastructure.-24-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONOur Innovation Factory supports the operating segments by developing superior enterprise-class solutions which are delivered to the our customers as stand-alone solutions or integrated with and aligned to product offerings through the operations of the business to meet complex customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, and cybersecurity. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions and works with customers to enhance solutions going forward. Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate. See Note 11â€”Business Segments Information to the condensed consolidated financial statements contained within this report for additional information. Economic Opportunities, Challenges, and RisksDuring the three and nine months ended NovemberÂ 1, 2024, we generated 98% of our revenues from contracts with the U.S. government, including subcontracts on which we perform. Our business performance is affected by the overall level of U.S. government spending and the alignment of our offerings and capabilities with the budget priorities of the U.S. government. In March 2024, the President signed appropriation measures that provide funding for government fiscal year ("GFY") 2024 for all of the U.S. government and submitted the GFY 2025 budget request which adheres to the Fiscal Responsibility Act of 2023. The GFY 2025 budget includes 1% growth for defense budgets and an overall 1% growth for non-defense budgets. In September 2024, the President signed a continuing

resolution which will fund the U.S. government under GFY 2024 levels through December 2024. If Congress is not able to pass appropriations for GFY 2025 funding by December 2024, it could result in the U.S. government operating on additional continuing resolutions and/or could potentially lead to a partial or full government shutdown. In addition, if full-year appropriations are not signed into law by April 30, 2025, a 1% sequestration would be applied to all agencies. In January 2023, the Federal debt ceiling was reached and the U.S. Department of the Treasury was operating under "extraordinary measures." In June 2023, the President signed the Fiscal Responsibility Act of 2023 which suspends the Federal debt ceiling until January 1, 2025, postponing the threat of a federal government default. If a new debt ceiling agreement is not reached by January 2025, the U.S. Department of the Treasury will return to operating under "extraordinary measures." Congressional debt limit

brinksmanship can lead to negative impacts on our business, and any agreement to raise the ceiling that significantly reduces future funding could affect our addressable market in subsequent years. Adverse changes in fiscal and economic conditions could materially impact our business. Some changes that could have an adverse impact on our business include adverse regulations, the implementation of future spending reductions (including sequestration), delayed passage of appropriations bills resulting in temporary or full-year continuing resolutions, extreme inflationary increases adversely impacting fixed price contracts, and potential government shutdowns. Spending packages, including the infrastructure bill, Inflation Reduction Act, and CHIPS and Science Act, as well as future potential spending packages, may provide additional opportunity in areas of SAIC focus such as digital modernization, cyber, microelectronics support, and climate resiliency. The U.S. government has increasingly relied on contracts that are subject to a competitive bidding process (including indefinite delivery, indefinite quantity ("IDIQ"), U.S. General Services Administration ("GSA") schedules, and other multi-award contracts), which has resulted in greater competition and increased pricing pressure. Additionally, the U.S. government has put renewed emphasis on increasing the number of small business prime set-aside contracts that further reduce the addressable market in some areas. Despite the budget and competitive pressures affecting the industry, we believe we are well-positioned to protect and expand existing customer relationships and benefit from opportunities that we have not previously pursued. Our scale, size, and prime contractor leadership position are expected to help differentiate us from our competitors, especially on large contract opportunities. We believe our long-term, trusted customer relationships and deep technical expertise provide us with the sophistication to handle highly complex, mission-critical contracts. Our value proposition is found in the proven ability to serve as a trusted adviser to our customers. In doing so, we leverage our expertise and scale to help them execute their mission.

-25-Table of ContentsSCIENCE APPLICATIONS

INTERNATIONAL CORPORATION We succeed as a business based on the solutions we deliver, our past performance, and our ability to compete on price. Our solutions are inspired through innovation based on adoption of best practices and technology integration of the best capabilities available. Our Innovation Factory develops superior enterprise-class solutions which are delivered to our customers as stand-alone solutions or integrated with and aligned to our product offerings to meet complex customer needs and accelerate the digital transformation. Our past

performance was achieved by employees dedicated to supporting our customers' most challenging missions. Our current cost structure and ongoing efforts to reduce costs by strategic sourcing and developing repeatable offerings sold "as a service" and as managed services in a more commercial business model are expected to allow us to compete effectively on price in an evolving environment. Our ability to be competitive in the future will continue to be driven by our reputation for successful program execution, competitive cost structure, development of new pricing and business models, and efficiencies in assigning the right people, at the right time, in support of our contracts. Management of Operating Performance and Reporting Our business and program management process is directed by professionals focused on serving our customers by providing high quality services in achieving program requirements. These professionals carefully monitor contract margin performance by constantly evaluating contract risks and opportunities. Throughout each contract's life cycle, program managers review performance and update contract performance estimates to reflect their understanding of the best information available. We evaluate our results of operations by considering the drivers causing changes in revenues, operating income, adjusted operating income(1), adjusted EBITDA(1), and operating cash flows. Given that revenues fluctuate on our contract portfolio over time due to contract awards and completions, changes in customer requirements, and increases or decreases in ordering volume of materials, we evaluate significant trends and fluctuations resulting from these factors. Whether performed by our employees or by our subcontractors, we primarily provide services and, as a result, our cost of revenues are predominantly variable. We also analyze our cost mix (labor, subcontractor and materials) in order to understand operating margin because programs with a higher proportion of SAIC labor are generally more profitable. Changes in cost of revenues as a percentage of revenues other than from revenue volume or cost mix are normally driven by fluctuations in shared or corporate costs, or cumulative revenue adjustments due to changes in estimates. Changes in operating cash flows are described with regard to changes in cash generated through the provision of services, significant drivers of fluctuations in assets or liabilities and the impacts of changes in timing of cash receipts or disbursements.

(1) Non-GAAP measure, see "Non-GAAP Measures" section below for additional information about this measure.

-26-Table of ContentsSCIENCE APPLICATIONS

INTERNATIONAL CORPORATION Condensed Consolidated Results of Operations The primary financial performance measures we use to manage our consolidated business and monitor results of operations are revenues, operating income, and cash flows from operating activities. The following table summarizes our condensed consolidated results of operations:

	Three Months Ended	Nine Months Ended	November
1,2024	Percent change	November 3, 2023	November 3, 2024
Revenues	\$1,976Â 4Â %	\$1,895Â \$5,641Â (1Â %)	\$5,707Â
Cost of revenues	1,739Â 4Â %	1,666Â 4,981Â (1Â %)	5,027Â
As a percentage of revenues	88.0Â %	87.9Â %	88.3Â %
Selling, general and administrative expenses	83Â (5Â %)	87Â 245Â (5Â %)	259Â (Gain) loss on divestitures, net of transaction costs
(240)	(100Â %)	(100Â %)	(100Â %)
Other operating (income) expense	(6)	500Â %	(10)
Operating income	160Â 12Â %	143Â 425Â (36Â %)	900Â %
160Â 12Â %	143Â 425Â (36Â %)	900Â %	(1) Operating income
662Â As a percentage of revenues	8.1Â %	7.5Â %	7.5Â %
11.6Â %	11.6Â %	11.6Â %	Provision for income taxes
(20)	(5Â %)	(5Â %)	(21)
(57Â %)	(134)	(57Â %)	(134)
Net income	\$106Â 14Â %	\$93Â \$264Â (40Â %)	\$438Â
Revenues	Revenues increased \$81 million for the three months ended NovemberÂ 1, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts, partially offset by contract completions. Revenues decreased \$66 million for the nine months ended NovemberÂ 1, 2024 as compared to the same period in the prior year primarily due to the sale of the Supply Chain Business (\$188Â million) in the prior year (see Note 4â€"Divestitures), and contract completions. This was partially offset by ramp up in volume on existing and new contracts. Adjusting for the impact of the divestiture, revenues grew 2.2%. Operating Income. Operating income as a percentage of revenues for the three months ended NovemberÂ 1, 2024 increased from the comparable prior year period primarily due to ramp up in volume on existing and new contracts, and the resolution of the Assault Amphibious Vehicle ("AAV") contract termination (see Note 12â€"Legal Proceedings and Other Commitments and Contingencies for additional information), partially offset by contract completions. Operating income as a percentage of revenues for the nine months ended NovemberÂ 1, 2024 decreased from the comparable prior year period primarily due to the prior year gains on the sale of the Supply Chain Business (\$233Â million) and deconsolidation of FSA (\$7Â million), and contract completions, partially offset by ramp up in volume on existing and new contracts. Income Taxes. Our effective income tax rate was 15.6% and 17.8% for the three and nine months ended NovemberÂ 1, 2024, respectively, and 18.0% and 23.4% for the three and nine months ended NovemberÂ 3, 2023, respectively. Our effective tax rate differs from the statutory tax rate primarily due to the deduction for foreign derived intangible income, research and development tax credits, and stock-based compensation windfalls. The effective tax rate in the prior year further differed from the statutory tax rate due to a gain from the disposition of the Supply Chain Business and the associated non-deductible goodwill. Our effective tax rate for the three and nine months ended NovemberÂ 1, 2024 decreased compared to the same periods in the prior year due to the non-recurrence of a gain from the disposition of the Supply Chain Business and the associated non-deductible goodwill. In addition, the effective tax rates for the three and nine months ended NovemberÂ 1, 2024 benefited from the release of certain state liabilities for uncertain tax positions.		
(27)	(27)	(27)	(27)
Net income	\$106Â 14Â %	\$93Â \$264Â (40Â %)	\$438Â
Revenues	Revenues increased \$36 million for the three months ended NovemberÂ 1, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts, partially offset by contract completions. Revenues decreased \$99 million for the nine months ended NovemberÂ 1, 2024 as compared to the same period in the prior year primarily due to the sale of the Supply Chain		

Business (\$188 million) in the prior year, and contract completions. This was partially offset by ramp up in volume on existing and new contracts. Adjusting for the impact of the divestiture, revenues grew 2.1%. Operating and adjusted operating income: Operating and adjusted operating income as a percentage of revenues for the three months ended November 1, 2024 increased from the comparable prior year period primarily due to ramp up in volume on existing and new contracts, and the resolution of the AAV contract termination, partially offset by contract completions. Operating and adjusted operating income as a percentage of revenues for the nine months ended November 1, 2024 increased from the comparable prior year period primarily due to ramp up in volume on existing and new contracts, and the resolution of the AAV contract termination, partially offset by contract completions and the gain on the sale of the Supply Chain Business in the prior year.-28-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION

CivilianThree Months EndedNine Months EndedNovember 1, 2024PercentchangeNovember 3, 2023(\$ millions)Revenues\$461Â 11Â %\$416Â 1,275Â 3Â %\$1,242Â Operating income37Â (31Â %)54Â 105Â (24Â %)139Â As a percentage of revenues8.0Â %13.0Â %8.2Â %11.2Â %Amortization of intangible assets12Â ¤"Â %12Â 36Â ¤"Â %36Â Adjusted operating income(1)\$49Â (26Â %)\$66Â \$141Â (19Â %)\$175Â As a percentage of revenues10.6Â %15.9Â %11.1Â %14.1Â %(1) Non-GAAP measure, see "Non-GAAP Measures" section below for additional information about this measure.Revenues: Revenues increased \$45 million for the three months ended November 1, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing contracts.Revenues increased \$33 million for the nine months ended November 1, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts, partially offset by contract completions.Operating and adjusted operating income: Operating and adjusted operating income as a percentage of revenues for the three months ended November 1, 2024 decreased from the comparable prior year period due to timing and volume mix.Operating and adjusted operating income as a percentage of revenues for the nine months ended November 1, 2024 decreased from the comparable prior year primarily due to timing and reduced volume on existing contracts. A CorporateThree Months EndedNine Months EndedNovember 1, 2024PercentchangeNovember 3, 2023(\$ millions)Operating (loss) income\$(7)(59Â %)\$(17)\$(24)113Â %\$187Â Depreciation of property, plant, and equipment5Â ¤"Â %5Â 16Â (11Â %)18Â Acquisition and integration costs(1)â€"Â ¤"Â %â€"Â (2)(300Â %)1Â Restructuring and impairment costsâ€"Â (100Â %)2Â 4Â (50Â %)8Â Recovery of acquisition and integration costs and restructuring and impairment costs(2)â€"Â (100Â %)(1)2)100Â %(1)(Gain) loss on divestitures, net of transaction costsâ€"Â ¤"Â %â€"Â (100Â %)(240)Adjusted operating loss(3)\$(2)82Â %\$11)\$(8)(70Â %)\$27)1Â ¤"Â Adjustment consists of a reversal of immaterial costs related to the Koverse acquisition.

(2)Â ¤"Â Adjustment reflects the portion of acquisition and integration costs and restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.(3)Â ¤"Â Non-GAAP measure, see "Non-GAAP Measures" section below for additional information about this measure.Operating and adjusted operating (loss) income: Operating and adjusted operating loss decreased \$10 million and \$9Â million, respectively, for the three months ended November 1, 2024 as compared to the same period in the prior year primarily due to lower selling, general and administrative expenses and a gain on sale of an equity method investment. Operating loss increased \$211 million for the nine months ended November 1, 2024 as compared to the same period in the prior year primarily due to the gain on the sale of the Supply Chain Business in the prior year (\$233Â million) and the gain recognized from the deconsolidation of FSA (\$7Â million), partially offset by lower selling, general and administrative expenses in the current year.-29-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Adjusted operating income decreased \$19Â million for the nine months ended November 1, 2024 as compared to the same period in the prior year primarily due to lower selling, general and administrative expenses in the current year.Non-GAAP MeasuresAdjusted operating income, earnings before interest, taxes, depreciation and amortization ("EBITDA"), and adjusted EBITDA are non-GAAP financial measures. While we believe that these non-GAAP financial measures are also useful for management and investors in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.Adjusted operating income. Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition and integration costs, impairments, restructuring costs, and any other material non-recurring costs. The acquisition and integration costs relate to the Company's acquisitions. The restructuring and impairment costs represent the reorganization and facilities optimization costs or impairments of long-lived assets. The recovery of acquisition and integration costs and restructuring and impairment costs relate to costs recovered through the Company's indirect rates in accordance with Cost Accounting Standards. Depreciation of property, plant, and equipment relates to property, plant, and equipment specifically identifiable for each segment. Adjusted operating income also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.EBITDA and Adjusted EBITDA. The performance measure EBITDA is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is performance measure that excludes costs that we do not consider to be indicative of our ongoing performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition and integration costs, impairments, restructuring costs, and any other material non-recurring costs. Integration costs are costs to integrate acquired companies including costs of strategic consulting services, facility consolidation and employee related costs such as retention and severance costs. The acquisition and integration costs relate to our acquisitions. We believe that EBITDA and adjusted EBITDA provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.-30-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION

EBITDA and adjusted EBITDA for the periods presented were calculated as follows:Â Three Months EndedNine Months EndedNovember 1, 2024November 3, 2023(\$ millions)Net income\$106Â \$93Â \$264Â \$438Â Interest expense, net and loss on sale of receivables36Â 29Â 108Â 95Â Provision for income taxes20Â 21Â 57Â 134Â Depreciation and amortization35Â 34Â 104Â 106Â EBITDA197Â 177Â 533Â 773Â EBITDA as a percentage of revenues10.0Â %9.3Â %9.4Â %13.5Â %Acquisition and integration costs(1)â€"Â ¤"Â (2)1Â Restructuring and impairment costsâ€"Â (2)Â 4Â 8Â Recovery of acquisition and integration costs and restructuring and impairment costs(2)â€"Â (1)(2)(1)(Gain) loss on divestitures, net of transaction costsâ€"Â ¤"Â (240)Adjusted EBITDA\$197Â \$178Â \$533Â \$541Â Adjusted EBITDA as a percentage of revenues10.0Â %9.4Â %9.4Â %9.5Â %(1)Â ¤"Â Adjustment consists of a reversal of immaterial costs related to the Koverse acquisition.

(2)Â ¤"Â Adjustment reflects the portion of acquisition and integration costs and restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.Adjusted EBITDA as a percentage of revenues for the three months ended November 1, 2024 increased compared to the same periods in the prior year primarily due to the resolution of the AAV contract termination, and ramp up in volume on existing and new contracts, partially offset by contract completions.Adjusted EBITDA as a percentage of revenues for the nine months ended November 1, 2024 decreased compared to the same periods in the prior year primarily due to contract completions, partially offset by the resolution of the AAV contract termination, and ramp up in volume on existing and new contracts.Other Key Performance MeasuresIn addition to the financial measures described above, we believe that bookings and backlog are useful measures for management and investors to evaluate our potential future revenues. We also consider measures such as contract types and cost of revenues mix to be useful for management and investors to evaluate our operating income and performance.Net Bookings and Backlog. Net bookings represent the estimated amount of revenues to be earned in the future from funded and negotiated unfunded contract awards that were received during the period, net of adjustments to estimates on previously awarded contracts. We calculate net bookings as the periodâ€™s ending backlog plus the periodâ€™s revenues less the prior periodâ€™s ending backlog and initial backlog obtained through acquisitions.Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is performed. We do not include in backlog estimates of revenues to be derived from IDIQ contracts, but rather record backlog and bookings when task orders are awarded on these contracts. Given that much of our revenue is derived from IDIQ contract task orders that renew annually, bookings on these contracts tend to refresh annually as the task orders are renewed. Additionally, we do not include in backlog contract awards that are under protest until the protest is resolved in our favor.-31-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION

We segregate our backlog into two categories as follows:â€¢Funded Backlog. Funded backlog for contracts with government agencies primarily represents estimated amounts of revenue to be earned in the future from contracts for which funding is appropriated less revenues previously recognized on these contracts. It does not include the unfunded portion of contracts in which funding is incrementally appropriated or authorized on a quarterly or annual basis by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government customers represents the estimated value on contracts, which may cover multiple future years, under which we are obligated to perform, less revenues previously recognized on these contracts.â€¢Negotiated Unfunded Backlog. Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from negotiated contracts for which funding has not been appropriated or otherwise authorized and from unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be

awarded under IDIQ, GSA Schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders. We expect to recognize revenue from a substantial portion of our funded backlog within the next twelve months. However, the U.S. government can adjust the scope of services or cancel contracts at any time. Similarly, certain contracts with commercial customers include provisions that allow the customer to cancel prior to contract completion. Most of our contracts have cancellation terms that would permit us to recover all or a portion of our incurred costs and fees (contract profit) for work performed. The estimated value of our total backlog as of the dates presented was: November 1, 2024February 2, 2024Defense and IntelligenceCivilianTotal SAICDefense and IntelligenceCivilianTotal SAIC (in millions)Funded backlog\$3,489\$ 977\$ 4,466\$ 2,707\$ 832\$ 3,539\$ Negotiated unfunded backlog14,822\$ 3,099\$ 17,921\$ 16,316\$ 2,908\$ 19,224\$ Total backlog\$18,311\$ 4,076\$ 22,387\$ 19,023\$ 3,740\$ 22,763\$ We had net bookings worth an estimated \$1.5 billion and \$5.3 billion during the three and nine months ended November 1, 2024, respectively. Contract Types. Our earnings and profitability may vary materially depending on changes in the proportionate amount of revenues derived from each type of contract. For a discussion of the types of contracts under which we generate revenues, see "Business - Contract Types" in Part I, Item 1 of the most recently filed Annual Report on Form 10-K. The following table summarizes revenues by contract type as a percentage of each reportable segment and total SAIC revenues for the periods presented:Three Months EndedNovember 1, 2024November 3, 2023Defense and IntelligenceCivilianTotal SAICDefense and IntelligenceCivilianTotal SAIC(in millions)Cost reimbursement82% 64% 64% 80% 64% 64% Time and materials ("T&M")8% 62% 21% 9% 60% 20% Firm-fixed price ("FFP")10% 32% 15% 11% 36% 16% Total100% 100% 100% 100% 100% 100% -32-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONNine Months EndedNovember 1, 2024November 3, 2023Defense and IntelligenceCivilianTotal SAICDefense and IntelligenceCivilianTotal SAIC(in millions)Cost reimbursement79% 66% 63% 76% 44% 60% Time and materials ("T&M")10% 64% 22% 8% 60% 19% Firm-fixed price ("FFP")11% 30% 15% 16% 36% 21% Total100% 100% 100% 100% 100% 100% The change in contract mix for the nine months ended November 1, 2024 is primarily due to a decrease in firm-fixed price type contracts due to the divestiture of the Supply Chain Business in the prior year, which historically had a higher proportion of these contracts. Cost of Revenues Mix. We generate revenues by providing a customized mix of services to our customers. The profit generated from our service contracts is affected by the proportion of cost of revenues incurred from the efforts of our employees (which we refer to below as labor-related cost of revenues), the efforts of our subcontractors and the cost of materials used in the performance of our service obligations under our contracts. Contracts performed with a higher proportion of SAIC labor are generally more profitable. The following table presents cost mix as a percentage of each reportable segment and total SAIC revenues for the periods presented:Three Months EndedNovember 1, 2024November 3, 2023Defense and IntelligenceCivilianTotal SAICDefense and IntelligenceCivilianTotal SAIC(in millions)Labor-related cost of revenues55% 55% 55% 55% 55% 56% Subcontractor-related cost of revenues29% 30% 29% 30% 35% 31% Other materials-related cost of revenues16% 15% 16% 15% 8% 13% Total100% 100% 100% 100% 100% 100% Nine Months EndedNovember 1, 2024November 3, 2023Defense and IntelligenceCivilianTotal SAICDefense and IntelligenceCivilianTotal SAIC(in millions)Labor-related cost of revenues56% 58% 56% 53% 58% 54% Subcontractor-related cost of revenues29% 31% 30% 30% 34% 31% Supply chain materials-related cost of revenues4% 4% 4% 4% 4% 4% Other materials-related cost of revenues15% 11% 14% 13% 8% 12% Total100% 100% 100% 100% 100% 100% The change in cost of revenues mix for the nine months ended November 1, 2024 is primarily due to a decrease in supply chain materials-related costs due to the divestiture of the Supply Chain Business in the prior year. Liquidity and Capital Resources As a services provider, our business generally requires minimal infrastructure investment. We expect to fund our ongoing working capital, commitments and any other discretionary investments with cash on hand, future operating cash flows and, if needed, borrowings under our \$1.0 billion Revolving Credit Facility and \$300 million MARPA Facility. We anticipate that our future cash needs will be for working capital, capital expenditures, and contractual and other commitments. We consider various financial measures when we develop and update our capital deployment strategy, which include evaluating cash provided by operating activities, free cash flow and financial leverage. -33-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION Our ability to fund these needs will depend, in part, on our ability to generate cash in the future, which depends on our future financial results. Our future results are subject to general economic, financial, competitive, legislative and regulatory factors that may be outside of our direct control. Although we believe that the financing arrangements in place will permit us to finance our operations on acceptable terms and conditions for at least the next year, our future access to, and the availability of financing on acceptable terms and conditions will be impacted by many factors (including our credit rating, capital market liquidity and overall economic conditions). Therefore, we cannot ensure that such financing will be available to us on acceptable terms or that such financing will be available at all. Nevertheless, we believe that our existing cash on hand, generation of future operating cash flows, and access to bank financing and capital markets will provide adequate resources to meet our short-term liquidity and long-term capital needs. During the first and third quarters of fiscal 2025, we amended our Credit Facility. See Note 7 "Debt Obligations to the condensed consolidated financial statements contained within this report for additional information. Historical Cash Flow Trends The following table summarizes our cash flows: Nine Months Ended November 1, 2024November 3, 2023 (in millions)Net cash provided by operating activities\$379\$ 333 Net cash (used in) provided by investing activities(15)324 Net cash used in financing activities(413)(455)Net (decrease) increase in cash, cash equivalents and restricted cash(\$49)\$202 Net Cash Provided by Operating Activities. Cash flows provided by operating activities increased \$46 million for the nine months ended November 1, 2024 as compared to the prior year primarily due to higher cash provided by the Master Accounts Receivable Purchase Agreement ("MARPA Facility") in the current year (see Note 10 "Sales of Receivables to the condensed consolidated financial statements contained within this report for additional information), and lower tax payments in the current year, partially offset by timing of customer collections and vendor payments, higher incentive-based compensation payments in the current year, and other changes in working capital. Net Cash (Used in) Provided by Investing Activities. Cash used in investing activities for the nine months ended November 1, 2024 was \$15 million compared to cash provided by investing activities of \$324 million in the prior year period. This change is primarily due to the \$356 million of cash proceeds for the sale of the Supply Chain Business in the prior year period (see Note 4 to the condensed consolidated financial statements). Net Cash Used in Financing Activities. Cash used in financing activities for the nine months ended November 1, 2024 decreased compared to the prior year period primarily due to higher proceeds received from borrowings, net of principal payments, partially offset by higher share repurchases in the current year. Critical Accounting Policies and Estimates There have been no changes to our critical accounting policies and estimates during the nine months ended November 1, 2024 from those disclosed in our most recently filed Annual Report on Form 10-K. Recently Issued But Not Yet Adopted Accounting Pronouncements For information on recently issued but not yet adopted accounting pronouncements, see Note 1 to the condensed consolidated financial statements contained within this report. Item 3. Quantitative and Qualitative Disclosures About Market Risk There have been no material changes to our market risks from those discussed in our most recently filed Annual Report on Form 10-K. -34-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION Item 4. Controls and Procedures Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) and have concluded that as of November 1, 2024 these controls and procedures were operating and effective. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarterly period covered by this report which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. -35-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION PART II OTHER INFORMATION Item 1. Legal Proceedings We have provided information about legal proceedings in which we are involved in our fiscal 2024 Annual Report on Form 10-K, and we have provided an update to this information in Note 12 "Legal Proceedings and Other Commitments and Contingencies to the condensed consolidated financial statements contained within this report, which is incorporated herein by reference. In addition to the described legal proceedings, we are routinely subject to investigations and reviews relating to compliance with various laws and regulations. Additional information regarding such investigations and reviews is included in our fiscal 2024 Annual Report on Form 10-K, and we have also updated this information in Note 12 "Legal Proceedings and Other Commitments and Contingencies to the condensed consolidated financial statements contained within this report, under the heading "Government Investigations, Audits and Reviews," which is incorporated herein by reference. Item 1A. Risk Factors There have been no material changes from the risk factors disclosed in our most recently filed Annual Report on Form 10-K. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Purchases of Equity Securities. We may repurchase shares on the open market in accordance with established repurchase plans. Whether repurchases are made and the timing and amount of repurchases depend on a variety of factors including market conditions, our capital position, internal cash generation and other factors. We also repurchase shares in connection with stock option and stock award activities to satisfy tax withholding obligations. The following table presents repurchases of our common stock during the three months ended November 1, 2024: Period(1)Total Number of Shares (or Units)Purchased(2)Average Price Paid per Share (or Unit)Total Number of Shares (or Units)Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number of Shares (or Units)that May Yet Be Purchased Under the Plans or Programs(3)August 3, 2024 - September 6, 2024 391,747\$ 126.00 389,574\$ 1,501,679 September 7, 2024 - October 4, 2024 259,610\$ 137.01 259,610\$ 1,242,069 October 5, 2024 -

November 1, 2024 210,004 145.23 210,004 1,032,065 Total 861,361 \$134.01 859,188 (1) Date ranges represent our fiscal periods during the current quarter. Our fiscal quarters typically consist of one five-week period and two four-week periods.(2)Includes shares purchased on surrender by stockholders of previously owned shares to satisfy minimum statutory tax withholding obligations related to stock option exercises and vesting of stock awards in addition to shares purchased under our publicly announced plans or programs.(3)In June 2022, the number of shares that may be purchased increased by 8.0 million shares, bringing the total authorized shares to be repurchased under the plan to approximately 24.4 million shares. As of November 1, 2024, we have repurchased approximately 23.4 million shares of common stock under the program.Item 3. Defaults Upon Senior SecuritiesNo information is required in response to this item.Item 4. Mine Safety DisclosuresNo information is required in response to this item.Item 5. Other InformationDuring the three months ended November 1, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as such terms are defined in Item 408 of Regulation S-K.-36-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATIONItem 6.

ExhibitsExhibit Number Description of Exhibit 3.1 Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 5, 2024.10.1 Seventh Amendment to the Third Amended and Restated Credit Agreement, dated October 18, 2024, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on October 22, 2024.31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101 Interactive Data File. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.104 The cover page from this Quarterly Report on Form 10-Q, formatted as Inline XBRL.-37-Table of ContentsSCIENCE APPLICATIONS INTERNATIONAL CORPORATION SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 5, 2024 Science Applications International Corporation /s/ Prabu Natarajan Prabu Natarajan Executive Vice President and Chief Financial Officer-38-Document Exhibit 31.1 SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002, Toni Townes-Whitley, certify that:1.I have reviewed this Quarterly Report on Form 10-Q for the period ended November 1, 2024 of Science Applications International Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: December 5, 2024 /s/ Toni Townes-Whitley Toni Townes-Whitley Chief Executive Officer Document Exhibit 31.2 SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002, Prabu Natarajan, certify that:1.I have reviewed this Quarterly Report on Form 10-Q for the period ended November 1, 2024 of Science Applications International Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: December 5, 2024 /s/ Prabu Natarajan Prabu Natarajan Chief Financial Officer Document Exhibit 32.1 SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, In connection with the Quarterly Report of Science Applications International Corporation (the "Company") on Form 10-Q for the period ended November 1, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Toni Townes-Whitley, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: December 5, 2024 /s/ Toni Townes-Whitley Toni Townes-Whitley Chief Executive Officer Document Exhibit 32.2 SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, In connection with the Quarterly Report of Science Applications International Corporation (the "Company") on Form 10-Q for the period ended November 1, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Prabu Natarajan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: December 5, 2024 /s/ Prabu Natarajan Prabu Natarajan Chief Financial Officer